Acquisition of Metastatic Properties via Somatic Cell Fusion: Implications for Tumor Progression in Vivo

Author(s):  
Patrick De Baetselier ◽  
Ed Roos ◽  
Hendrik Verschueren ◽  
Steven Verhaegen ◽  
Daniel Dekegel ◽  
...  
2010 ◽  
Vol 54 (11-12) ◽  
pp. 1723-1728 ◽  
Author(s):  
Huseyin Sumer ◽  
Craig Nicholls ◽  
Jun Liu ◽  
Pollyanna A. Tat ◽  
Jun-Ping Liu ◽  
...  

2003 ◽  
Vol 10 (2) ◽  
pp. 253-259 ◽  
Author(s):  
June L. Traicoff ◽  
Sumudra Periyasamy ◽  
Michael G. Brattain ◽  
William Grady ◽  
Graham Casey

Stem Cells ◽  
2008 ◽  
Vol 26 (3) ◽  
pp. 775-782 ◽  
Author(s):  
Emma J. Bowles ◽  
R. Tayfur Tecirlioglu ◽  
Andrew J. French ◽  
Michael K. Holland ◽  
Justin C. St. John

2020 ◽  
Author(s):  
Antonio Serrano ◽  
Hamzeh H. Hammadeh ◽  
Natalie Schwarz ◽  
Ulrike Brandt ◽  
André Fleißner

AbstractSomatic cell fusion is widely studied in the filamentous fungus Neurospora crassa. The interaction of genetically identical germlings is mediated by a signaling mechanism in which the cells take turns in signal-sending and receiving. The switch between these physiological states is represented by the alternating membrane recruitment of the SO protein and the MAPK MAK-2. This dialog-like behavior is observed until the cells establish physical contact, when the cell-wall-integrity MAK-1 is recruited to the contact area to control the final steps of the cell fusion process. This work revealed, for the first-time, an additional MAK-1-function during the tropic growth phase. Specific inhibition of MAK-1 during tropic-growth resulted in disassembly of the actin-aster, and mislocalization of SO and MAK-2. Similar defects were observed after the inhibition of the Rho-GTPase RAC-1, suggesting a functional link between them, being MAK-1 upstream of RAC-1. In contrast, after inhibition of MAK-2, the actin-aster stayed intact, however, its subcellular localization became instable within the cell-membrane. Together these observations led to a new working model, in which MAK-1 promotes the formation and stability of the actin-aster, while MAK-2 controls its positionning and cell growth directionality.Summary statementThe CWI MAPK MAK-1 pathway controls actin cytoskeleton assembly at the cell tips through activation of the Rho-GTPase RAC-1 exclusively on somatic cell fusion.


1990 ◽  
Vol 64 (02) ◽  
pp. 260-266 ◽  
Author(s):  
Elizabeth E Branscomb ◽  
Marschall S Runge ◽  
Christopher E Savard ◽  
Keith M Adams ◽  
Gary R Matsueda ◽  
...  

SummaryBispecific monoclonal antibodies that bind simultaneously to human fibrin and tissue plasminogen activator (tPA) enhance the fibrinolytic potency of tPA. Two bispecific antibodies (F36.23 and F32.1) were generated by somatic cell fusion. Antibody F36.23 derives its tPA binding from monoclonal anti-tPA antibody TCL8 and its fibrin binding from monoclonal antifibrin antibody 59D8. After purification from cell supernatants and ascites by two steps of affinity chromatography, hybrid-hybridoma bispecific antibody F36.23 simultaneously bound tPA and fibrin in solution and in solid-phase assays. In an assay for the lysis of human fibrin monomer, F36.23 increased the fibrinolytic potency of tPA by 5 to 10 fold, regardless of whether the bispecific antibody had been combined with the tPA before or during the assay. Bispecific F36.23 F(ab′)2 also bound tPA and fibrin simultaneously, and the enhancement in fibrinolysis in the presence of F36.23 F(ab′)2 was identical to that in the presence of intact F36.23. The second bispecific antibody, F32.1, was produced by an alternative strategy that has a wider potential for applicaton in other systems. Hybridoma bispecific antibody F32.1 was derived from the fusion of immune splenocytes (in mice immunized with a synthetic oligopeptide representing the amino terminus of the α-chain of human fibrin) with the anti-tPA cell line TCL8. The properties of hybridoma bispecific antibody F32.1 and its F(ab′)2 were indistinguishable from those of hybrid-hybridoma bispecific antibody F36.23 in solid-phase binding assays and in assays of fibrinolysis. Bispecific antibodies produced by somatic cell fusion, particularly in the form of F(ab′)2, may have potential for use in clinical thrombolysis.


Author(s):  
J. M. Tager ◽  
A. Westerveld ◽  
A. Strijland ◽  
A. W. Schram ◽  
R. B. H. Schutgens ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document